Company Overview
BioLineRx Ltd. operates as a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutics specifically targeting oncology and rare diseases. The company functions within the Healthcare sector, more precisely in the Biotechnology industry, an environment characterized by high R&D expenditures and significant regulatory hurdles before products reach market. Currently, the enterprise maintains a market capitalization of $10.66M and reported annual revenue of $1.18M, with no specific employee count available in public filings. These valuation and revenue figures indicate that the company is a micro-cap entity with limited scale, suggesting a business model that relies heavily on future clinical trial successes to achieve substantial commercial expansion rather than current operational volume.
Financial Health
The company reported revenue of $1.18M over the trailing twelve months, while recording a net income of $-1,175,000 and an EBITDA of $-10,060,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure dominated by non-operating expenses or significant impairments that exceed gross profits, a common trait in biotechnology firms during clinical development phases. Free cash flow stands at $-3,875,250, indicating that the company is currently burning cash to fund its operations and research activities, which limits immediate financial flexibility but is often necessary for advancing clinical pipelines. Gross margin is reported at 80.5%, reflecting the typical high-margin nature of biotech products before accounting for research costs, whereas the operating margin of -1745.4% and profit margin of -99.6% highlight severe operational inefficiencies or one-time charges relative to the small revenue base. The balance sheet holds $20.88M in cash against $10.15M in debt, resulting in a debt-to-equity ratio of 43.48, which suggests a moderately leveraged position given the lack of earnings to service that debt. Current ratio is 1.95, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities with nearly double the necessary liquidity buffer. Return on Equity is -11.0% and Return on Assets is -16.1%, metrics that reveal that management is currently generating negative returns on the capital invested, consistent with a company in a growth stage that has not yet achieved profitability.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -3.54, implying that the market is pricing in future earnings recovery or continuing losses based on analyst expectations. The Price to Book ratio is 338.57, indicating a substantial market premium over the company's book value, which is typical for biotech assets where future pipeline potential is valued far above current asset totals. The Price to Sales ratio is 9.04 and EV/EBITDA is -614.52, suggesting that traditional valuation metrics are distorted by the company's loss-making status and high enterprise value relative to earnings. The 52-Week High is $7.77 and the 52-Week Low is $2.30, meaning the current trading price sits within this historical range, fluctuating between these established volatility boundaries. The Beta is 0.46, which indicates that the stock's price volatility is significantly lower than the broader market, moving at less than half the intensity of the overall market index.
Growth & Income
Revenue Growth (YoY) is -98.3% and Earnings Growth (YoY) is N/A, reflecting the company's transition from a previous revenue model or the impact of recognizing specific clinical costs that have reduced top-line figures compared to the prior period. Since earnings growth data is not available due to N/A earnings figures, it is impossible to determine if earnings are growing faster or slower than revenue, though the negative revenue growth suggests a contraction in commercial sales or a shift in revenue recognition timing. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, as biotechnology companies at this stage typically reinvest all available capital into research and development rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for clinical milestones and commercial partnerships rather than current cash flow generation or dividend distributions.